ArticleFrontiers in oncology2023

Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report.

Myriam Mirza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.